Nathan Ball Z Personal Training

Natural daylight changed metabolism in people with type 2 diabetes even though the intervention was simply the light they worked under.

Researchers enrolled 13 adults with type 2 diabetes in a randomized crossover trial. Each person spent 4.5 working days exposed to natural daylight through windows and another 4.5 days under constant artificial office lighting.

The clearest glucose finding came from continuous glucose monitoring. Participants spent 50.9% of the time between 80 and 130 mg/dL under natural daylight, compared with 43.3% under artificial light. Average glucose, however, was not significantly different. And when the broader current diabetes target range of 70–180 mg/dL was used, the difference was 83.0% versus 78.6% and did not reach statistical significance. CGM data were available for 10 participants.

The metabolic response went beyond glucose. During the daylight condition, whole-body fuel use shifted toward greater fat oxidation, evening melatonin concentrations were higher, and skeletal-muscle and blood measurements showed changes consistent with altered circadian and metabolic signaling.

That makes the result interesting because light is usually discussed as a sleep or circadian signal. This experiment suggests the daytime light environment may also influence how the body handles fuel.

this was a very small, short study. The participants were also older, with an average age around 70, and each lighting condition lasted only 4.5 days. There is no evidence yet that working beside a window lowers HbA1c or prevents diabetes complications over the long term.

So the finding is not that daylight treats diabetes. It is that the built environment may be one more input into human metabolism, and natural daylight is now interesting enough to test in larger, longer trials.

Harmsen JF et al. Cell Metabolism. 2026;38(1):65-81.e10. PMID 41418772.

MUSCLE IS THE ORGAN OF HEALTH, VITALITY, & LONGEVITY

For decades, building muscle was treated like something you did because you wanted bigger arms or wanted to look better naked.

Turns out, that dramatically undersells what skeletal muscle does.

Skeletal muscle is a major regulator of glucose metabolism, responsible for approximately 80% of post-meal glucose uptake from circulation. Muscle insulin resistance plays a major role in metabolic disease. (PMID: 32940941)

Resistance training also helps preserve and increase bone mineral density, an increasingly important benefit as we age. (PMID: 35742181)

Then there’s independence.

Low muscle mass is associated with greater functional impairment and physical disability, while progressive resistance training can improve strength and reduce physical disability in older adults. (PMIDs: 12028177, 20476841)

Then there’s LIFE.

People who perform muscle-strengthening activity have approximately a 10–17% lower risk of all-cause mortality and several major chronic diseases compared with those who don’t. Higher muscular strength itself is also consistently associated with lower mortality risk. (PMIDs: 35228201, 29425700)

And your brain benefits too.

Resistance training improves several measures of cognitive function in older adults, while lower strength predicts greater cognitive decline and future dependency. (PMIDs: 33325273, 20219767)

None of this means having huge muscles makes you immortal.

It means muscle and strength are FAR more important to lifelong health than the old “lifting weights is just for vanity” stereotype suggests.

And yeah…

Looking jacked is still a pretty nice side effect. 😂

Don’t just build muscle for the mirror.

BUILD MUSCLE FOR LIFE

For 50 years, eggs were treated like a cardiovascular threat. The 1960s dietary guidelines capped cholesterol intake at 300mg per day. Two eggs put you at the limit. The advice moved millions away from the food, and away from a nutrient profile we didn't fully appreciate at the time.

A new study from Loma Linda University followed 39,498 adults age 65 and older for 15.3 years. The team linked Adventist Health Study-2 dietary records with Medicare diagnoses. Over that window, 2,858 participants developed Alzheimer's disease.

The dose-response was clean.
Eating eggs 1 to 3 times a month: 17% lower incidence vs never-eaters.
2 to 4 per week: 20% lower.

5 or more per week, roughly one a day: 27% lower.
The mechanism story isn't new, but the cohort scale and 15-year follow-up are. Eggs are the densest natural source of choline in the American diet. One large egg supplies roughly 33% of the daily choline requirement. Choline is the substrate for acetylcholine, the neurotransmitter that drops in Alzheimer's. Donepezil, the most prescribed Alzheimer's drug, works by blocking acetylcholine breakdown. The disease is partly defined by cholinergic neuron loss.

Egg yolk also delivers lutein and zeaxanthin. These are the only two carotenoids that cross the blood-brain barrier and accumulate in cortical tissue. Higher tissue levels track with better processing speed and memory across multiple older-adult cohorts. Yolk also contains DHA, primarily in phospholipid form. Phospholipid DHA enters the brain more efficiently than DHA in triglyceride form, which is the dominant form in fish oil capsules.

Now the caveats, because they matter.
This is observational. Causation cannot be drawn from a cohort study. The Adventist Health Study-2 cohort skews heavily vegetarian and health-conscious, so people who eat eggs in this cohort do not look like the average American egg-eater. The "never eats eggs" comparison group is largely vegan, which is its own dietary pattern with its own complications. Reverse causation also has to be considered. People in early Alzheimer's often change eating patterns before diagnosis. Some of the apparent protection could be that healthier brains keep eating eggs, not the other way around.

The mechanism story I outlined above is supported by adjacent literature, not by this paper. The study did not measure choline status, lutein levels, or DHA in tissue. It measured eggs in, dementia out.

What we can say honestly: in a 40,000-person cohort followed for 15 years, egg intake tracked with substantially lower Alzheimer's incidence in a dose-response pattern. The mechanism is biochemically plausible, supported by other lines of evidence, and consistent with what we know about acetylcholine and brain carotenoid status. The randomized trial that would prove causation has not been run.

The practical version: if you are over 50 and not allergic, eating an egg most days has stronger evidence behind it for brain health than most products marketed for the same goal. Five days a week was the dose with the lowest risk in this cohort. Even 1 to 3 per month showed measurable benefit.

For 50 years the question was whether eggs were dangerous to your heart. The data behind that fear was always weaker than the guidelines made it sound, which is why the 2015 Dietary Guidelines for Americans quietly removed the 300mg cap. The brain question got asked too late.

Oh et al., J Nutr, 2026 (DOI: 10.1016/j.tjnut.2026.101541)

Two particles can carry the exact same amount of cholesterol and do very different damage to an artery. The blood test almost everyone gets measures the cholesterol. It does not measure the thing that actually varies: what kind of particle is carrying it.

Every particle that can build plaque, whether it is LDL, a triglyceride-rich remnant, or lipoprotein(a), carries exactly one molecule of a protein called apolipoprotein B, or apoB. One particle, one apoB.

That is what makes apoB useful: it is a direct headcount of how many plaque-causing particles are in your blood. A standard cholesterol panel does something different. It weighs the total cholesterol those particles are hauling, not how many particles there are. Most of the time the two line up. When they do not, decades of data say the same thing: risk follows the particle count, not the cholesterol number. This is the finding that reframes the whole panel, because it means a normal LDL cholesterol can sit on top of a high particle count, and the standard test will read reassuring while the risk is real.

The next question is whether every particle in that count is equally dangerous, and it is not.

LDL is the baseline. It enters the artery wall, can lodge there, and drives plaque, and because it is the most common apoB particle, it makes up the bulk of the count for most people. It is the reference against which the others are judged.

Remnants are worse, particle for particle. These are the leftovers of triglyceride-rich lipoproteins, larger particles that have dropped their fat and are on their way to being cleared. They are retained in the artery wall more readily than LDL, they carry more cholesterol per particle, and they provoke inflammation and foam-cell formation once they are stuck. They contribute to cardiovascular risk beyond what LDL cholesterol captures, which is why someone with normal LDL cholesterol but high triglycerides, common with insulin resistance and metabolic syndrome, can be carrying a risk their panel understates.

Lipoprotein(a), or Lp(a), is the one that does far more damage, and it is different in kind, not just degree. It is an LDL particle with an extra protein tail, apo(a), wrapped around it, and that tail resembles a clotting protein, adding a pro-thrombotic dimension the other particles do not have. The evidence that it causes disease is not just association. Genetic studies, which track people who inherited high Lp(a) from birth, show it is a direct causal driver, and high levels predict roughly a two- to threefold increase in the risk of heart attack, peripheral artery disease, and calcific aortic valve stenosis. And here is the part that matters for anyone reading this: your Lp(a) level is set almost entirely by your genes, diet and exercise barely move it, and roughly one in five people carry a high level. It is one of the strongest inherited cardiovascular risk factors there is, and it is measured with a single blood test that most people have never had ordered.

Particle count and particle type sharpen risk assessment, but they do not replace the rest of the picture, blood pressure, smoking, and the standard lipids still matter, and no single marker decides an individual's fate. And identifying a high-risk particle is not the same as having a proven way to lower the risk it carries. LDL and remnants respond to established therapies, but targeted Lp(a)-lowering drugs are still in trials, and until those trials report, a high Lp(a) is information that sharpens prevention rather than a number with its own treatment. The practical reframe stands anyway. The standard panel counts cholesterol and treats every apoB particle as interchangeable. They are not. Two of the three particles that matter most, remnants and Lp(a), are the ones a routine cholesterol number is least equipped to see.

Glavinovic et al., J Am Heart Assoc 2022
Cantey & Wilkins, Curr Opin Endocrinol Diabetes Obes 2018
Pinto et al., Clin Investig Arterioscler 2023
Kamstrup, Clin Chem 2021

Nobody warns you that your 20s lie to you.

You can skip the gym for a month, eat like garbage, cancel plans with people you care about, and stay stuck doing the same easy version of your life — and nothing happens. You feel fine.

You look fine. So you assume that's just how it works.

Then one day it isn't. The body stops absorbing the neglect quietly. The relationships you never invested in aren't there when you need them. The hobbies you never picked up leave you with nothing but work. It doesn't happen all at once. It happens slowly enough that you don't notice until you look up and the bill's due.

None of the basics feel urgent in the moment. Lifting weights. A weekly night with your spouse.

A smaller circle of people who actually know you. A hobby that's yours and nobody else's. Skip any one of them today and nothing breaks.

But they're not optional. They're just deferred.

-Coach Jon

The mechanism is not disputed. Every cardiologist alive agrees an LDL particle has to oxidise before the artery wall traps it. Every chemist alive agrees a saturated fat cannot perform that reaction, because there's nothing on the molecule to oxidise.

Only polyunsaturated fats can. Linoleic acid is the one on the shelf.

Butter cannot do the chemistry. Sunflower oil is designed for it.

The public health advice for fifty years has been to swap the fat that cannot cause the disease for the fat that mechanistically must.

The Lancet paper in 1994 said this plainly. Nobody in charge reconsidered a single guideline.